Skip to main content
SpringerLink
Log in

Hepatocellular Carcinoma

  • Chapter
  • First Online:
Textbook of Gastrointestinal Oncology

  • 876 Accesses

Abstract

Worldwide, hepatocellular carcinoma (HCC) is the sixth most common cancer and the second most common cause of cancer mortality, with a very poor survival rate. Many factors increasing the risk of HCC are classified into two groups: preventable and non-preventable. Unfortunately, HCC incidence is steadily increasing throughout the world. Therefore, many different kinds of HCC treatment are being evaluated to establish the optimal modality, reduce the development of new tumors, and prevent recurrence after surgical resection or liver transplantation. Basically, the treatment options for HCC are categorized as surgical or nonsurgical. Surgical therapies encompass resection and liver transplantation, whereas nonsurgical therapies include ablation techniques, transarterial therapies, irradiation, and systemic therapy including chemotherapy and molecularly targeted therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in globocan 2012. Int J Cancer. 2015;136(5):E359–86.

    Article  CAS  PubMed  Google Scholar 

  2. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-pd-l1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Custer B, Sullivan SD, Hazlet TK, Iloeje U, Veenstra DL, Kowdley KV. Global epidemiology of hepatitis b virus. J Clin Gastroenterol. 2004;38(10 Suppl 3):S158–68.

    Article  PubMed  Google Scholar 

  4. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007;132(7):2557–76.

    Article  CAS  PubMed  Google Scholar 

  5. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis b virus DNA level. JAMA. 2006;295(1):65–73.

    Article  CAS  PubMed  Google Scholar 

  6. Ayub A, Ashfaq UA, Haque A. Hbv induced hcc: major risk factors from genetic to molecular level. Biomed Res Int. 2013;2013:810461.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011;365(12):1118–27.

    Article  CAS  PubMed  Google Scholar 

  8. Lavanchy D. Hepatitis b virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004;11(2):97–107.

    Article  CAS  PubMed  Google Scholar 

  9. Beasley RP. Hepatitis b virus. The major etiology of hepatocellular carcinoma. Cancer. 1988;61(10):1942–56.

    Article  CAS  PubMed  Google Scholar 

  10. Poon RT, Fan ST, Wong J. Selection criteria for hepatic resection in patients with large hepatocellular carcinoma larger than 10 cm in diameter. J Am Coll Surg. 2002;194(5):592–602.

    Article  PubMed  Google Scholar 

  11. Yeh CN, Lee WC, Chen MF. Hepatic resection and prognosis for patients with hepatocellular carcinoma larger than 10 cm: two decades of experience at chang gung memorial hospital. Ann Surg Oncol. 2003;10(9):1070–6.

    Article  PubMed  Google Scholar 

  12. Theise N, Curado M, Franceschi S, Hytiroglou P, Kudo M, Park Y, et al. In who classification of tumors of the digestive system. In: Bosman F, Carneiro F, Hruban H, Theise N, editors. Hepatocellular carcinoma. 4th ed. Lyon: IARC; 2010.

    Google Scholar 

  13. Ishak K, Goodman Z, Stocker J. In tumors of the liver and intrahepatic bile ducts. In: Ishak K, Goodman Z, Stocker J, editors. Hepatocellular carcinoma. 3rd ed. Washington, DC: Armed Forces Institute of Pathology; 2001. p. 199–245.

    Google Scholar 

  14. Coston WM, Loera S, Lau SK, Ishizawa S, Jiang Z, Wu CL, et al. Distinction of hepatocellular carcinoma from benign hepatic mimickers using glypican-3 and cd34 immunohistochemistry. Am J Surg Pathol. 2008;32(3):433–44.

    Article  PubMed  Google Scholar 

  15. Shahid M, Mubeen A, Tse J, Kakar S, Bateman AC, Borger D, et al. Branched chain in situ hybridization for albumin as a marker of hepatocellular differentiation: evaluation of manual and automated in situ hybridization platforms. Am J Surg Pathol. 2015;39(1):25–34.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Evason KJ, Grenert JP, Ferrell LD, Kakar S. Atypical hepatocellular adenoma-like neoplasms with beta-catenin activation show cytogenetic alterations similar to well-differentiated hepatocellular carcinomas. Hum Pathol. 2013;44(5):750–8.

    Article  CAS  PubMed  Google Scholar 

  17. Kakar S, Gown AM, Goodman ZD, Ferrell LD. Best practices in diagnostic immunohistochemistry: hepatocellular carcinoma versus metastatic neoplasms. Arch Pathol Lab Med. 2007;131(11):1648–54.

    PubMed  Google Scholar 

  18. Abou-Alfa GKPT, Shindoh J, Vauthey J-N. Liver. In: Amin MBES, Greene FL, Byrd DR, Brookland RK, Washington MK, et al., editors. Ajcc cancer staging manual. 8th ed. New York: Springer; 2017. p. 287–93.

    Chapter  Google Scholar 

  19. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346(16):1221–31.

    Article  CAS  PubMed  Google Scholar 

  20. Tateishi R, Okanoue T, Fujiwara N, Okita K, Kiyosawa K, Omata M, et al. Clinical characteristics, treatment, and prognosis of non-b, non-c hepatocellular carcinoma: a large retrospective multicenter cohort study. J Gastroenterol. 2015;50(3):350–60.

    Article  CAS  PubMed  Google Scholar 

  21. Kew MC. Epidemiology of hepatocellular carcinoma in sub-saharan africa. Ann Hepatol. 2013;12(2):173–82.

    Article  PubMed  Google Scholar 

  22. Nagasue N, Ito A, Yukaya H, Ogawa Y. Androgen receptors in hepatocellular carcinoma and surrounding parenchyma. Gastroenterology. 1985;89(3):643–7.

    Article  CAS  PubMed  Google Scholar 

  23. Nagasue N, Ito A, Yukaya H, Ogawa Y. Estrogen receptors in hepatocellular carcinoma. Cancer. 1986;57(1):87–91.

    Article  CAS  PubMed  Google Scholar 

  24. Eagon PK, Elm MS, Epley MJ, Shinozuka H, Rao KN. Sex steroid metabolism and receptor status in hepatic hyperplasia and cancer in rats. Gastroenterology. 1996;110(4):1199–207.

    Article  CAS  PubMed  Google Scholar 

  25. Ostrowski JL, Ingleton PM, Underwood JC, Parsons MA. Increased hepatic androgen receptor expression in female rats during diethylnitrosamine liver carcinogenesis. A possible correlation with liver tumor development. Gastroenterology. 1988;94(5 Pt 1):1193–200.

    Article  CAS  PubMed  Google Scholar 

  26. Tejura S, Rodgers GR, Dunion MH, Parsons MA, Underwood JC, Ingleton PM. Sex-steroid receptors in the diethylnitrosamine model of hepatocarcinogenesis: modifications by gonadal ablation and steroid replacement therapy. J Mol Endocrinol. 1989;3(3):229–37.

    Article  CAS  PubMed  Google Scholar 

  27. Nakatani T, Roy G, Fujimoto N, Asahara T, Ito A. Sex hormone dependency of diethylnitrosamine-induced liver tumors in mice and chemoprevention by leuprorelin. Japanese J Cancer Res: Gann. 2001;92(3):249–56.

    Article  CAS  Google Scholar 

  28. Bruix J, Sherman M, American Association for the Study of Liver D. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53(3):1020–2.

    Article  PubMed  Google Scholar 

  29. Mazzaferro V, Lencioni R, Majno P. Early hepatocellular carcinoma on the procrustean bed of ablation, resection, and transplantation. Semin Liver Dis. 2014;34(4):415–26.

    Article  PubMed  Google Scholar 

  30. Munene G, Vauthey JN, Dixon E. Summary of the 2010 ahpba/sso/ssat consensus conference on hcc. Int J Hepatol. 2011;2011:565060.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Teh SH, Christein J, Donohue J, Que F, Kendrick M, Farnell M, et al. Hepatic resection of hepatocellular carcinoma in patients with cirrhosis: model of end-stage liver disease (meld) score predicts perioperative mortality. J Gastrointest Surg. 2005;9(9):1207–15; discussion 1215.

    Article  PubMed  Google Scholar 

  32. Cucchetti A, Ercolani G, Vivarelli M, Cescon M, Ravaioli M, La Barba G, et al. Impact of model for end-stage liver disease (meld) score on prognosis after hepatectomy for hepatocellular carcinoma on cirrhosis. Liver Transpl. 2006;12(6):966–71.

    Article  PubMed  Google Scholar 

  33. Ishizawa T, Hasegawa K, Aoki T, Takahashi M, Inoue Y, Sano K, et al. Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. Gastroenterology. 2008;134(7):1908–16.

    Article  PubMed  Google Scholar 

  34. Palavecino M, Chun YS, Madoff DC, Zorzi D, Kishi Y, Kaseb AO, et al. Major hepatic resection for hepatocellular carcinoma with or without portal vein embolization: perioperative outcome and survival. Surgery. 2009;145(4):399–405.

    Article  PubMed  Google Scholar 

  35. Yoo H, Kim JH, Ko GY, Kim KW, Gwon DI, Lee SG, et al. Sequential transcatheter arterial chemoembolization and portal vein embolization versus portal vein embolization only before major hepatectomy for patients with hepatocellular carcinoma. Ann Surg Oncol. 2011;18(5):1251–7.

    Article  PubMed  Google Scholar 

  36. Ogata S, Belghiti J, Farges O, Varma D, Sibert A, Vilgrain V. Sequential arterial and portal vein embolizations before right hepatectomy in patients with cirrhosis and hepatocellular carcinoma. Br J Surg. 2006;93(9):1091–8.

    Article  CAS  PubMed  Google Scholar 

  37. Makuuchi M, Hasegawa H, Yamazaki S. Ultrasonically guided subsegmentectomy. Surg Gynecol Obstet. 1985;161(4):346–50.

    CAS  PubMed  Google Scholar 

  38. Imamura H, Matsuyama Y, Miyagawa Y, Ishida K, Shimada R, Miyagawa S, et al. Prognostic significance of anatomical resection and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma. Br J Surg. 1999;86(8):1032–8.

    Article  CAS  PubMed  Google Scholar 

  39. Shindoh J, Makuuchi M, Matsuyama Y, Mise Y, Arita J, Sakamoto Y, et al. Complete removal of the tumor-bearing portal territory decreases local tumor recurrence and improves disease-specific survival of patients with hepatocellular carcinoma. J Hepatol. 2016;64(3):594–600.

    Article  PubMed  Google Scholar 

  40. Kang CM, Choi GH, Kim DH, Choi SB, Kim KS, Choi JS, et al. Revisiting the role of nonanatomic resection of small (< or = 4 cm) and single hepatocellular carcinoma in patients with well-preserved liver function. J Surg Res. 2010;160(1):81–9.

    Article  PubMed  Google Scholar 

  41. Dahiya D, Wu TJ, Lee CF, Chan KM, Lee WC, Chen MF. Minor versus major hepatic resection for small hepatocellular carcinoma (hcc) in cirrhotic patients: a 20-year experience. Surgery. 2010;147(5):676–85.

    Article  PubMed  Google Scholar 

  42. Cucchetti A, Qiao GL, Cescon M, Li J, Xia Y, Ercolani G, et al. Anatomic versus nonanatomic resection in cirrhotic patients with early hepatocellular carcinoma. Surgery. 2014;155(3):512–21.

    Article  PubMed  Google Scholar 

  43. Poon RT, Fan ST, Ng IO, Wong J. Significance of resection margin in hepatectomy for hepatocellular carcinoma: a critical reappraisal. Ann Surg. 2000;231(4):544–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Nara S, Shimada K, Sakamoto Y, Esaki M, Kishi Y, Kosuge T, et al. Prognostic impact of marginal resection for patients with solitary hepatocellular carcinoma: evidence from 570 hepatectomies. Surgery. 2012;151(4):526–36.

    Article  PubMed  Google Scholar 

  45. Shi M, Guo RP, Lin XJ, Zhang YQ, Chen MS, Zhang CQ, et al. Partial hepatectomy with wide versus narrow resection margin for solitary hepatocellular carcinoma: a prospective randomized trial. Ann Surg. 2007;245(1):36–43.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Capussotti L, Muratore A, Amisano M, Polastri R, Bouzari H, Massucco P. Liver resection for hepatocellular carcinoma on cirrhosis: analysis of mortality, morbidity and survival--a european single center experience. Eur J Surg Oncol. 2005;31(9):986–93.

    Article  CAS  PubMed  Google Scholar 

  47. Katz SC, Shia J, Liau KH, Gonen M, Ruo L, Jarnagin WR, et al. Operative blood loss independently predicts recurrence and survival after resection of hepatocellular carcinoma. Ann Surg. 2009;249(4):617–23.

    Article  PubMed  Google Scholar 

  48. Wang J, Xu LB, Liu C, Pang HW, Chen YJ, Ou QJ. Prognostic factors and outcome of 438 chinese patients with hepatocellular carcinoma underwent partial hepatectomy in a single center. World J Surg. 2010;34(10):2434–41.

    Article  PubMed  Google Scholar 

  49. Fan ST, Mau Lo C, Poon RT, Yeung C, Leung Liu C, Yuen WK, et al. Continuous improvement of survival outcomes of resection of hepatocellular carcinoma: a 20-year experience. Ann Surg. 2011;253(4):745–58.

    Article  PubMed  Google Scholar 

  50. Kluger MD, Salceda JA, Laurent A, Tayar C, Duvoux C, Decaens T, et al. Liver resection for hepatocellular carcinoma in 313 western patients: tumor biology and underlying liver rather than tumor size drive prognosis. J Hepatol. 2015;62(5):1131–40.

    Article  PubMed  Google Scholar 

  51. Ng KK, Vauthey JN, Pawlik TM, Lauwers GY, Regimbeau JM, Belghiti J, et al. Is hepatic resection for large or multinodular hepatocellular carcinoma justified? Results from a multi-institutional database. Ann Surg Oncol. 2005;12(5):364–73.

    Article  PubMed  Google Scholar 

  52. Shindoh J, Andreou A, Aloia TA, Zimmitti G, Lauwers GY, Laurent A, et al. Microvascular invasion does not predict long-term survival in hepatocellular carcinoma up to 2 cm: reappraisal of the staging system for solitary tumors. Ann Surg Oncol. 2013;20(4):1223–9.

    Article  PubMed  Google Scholar 

  53. Pawlik TM, Poon RT, Abdalla EK, Ikai I, Nagorney DM, Belghiti J, et al. Hepatectomy for hepatocellular carcinoma with major portal or hepatic vein invasion: results of a multicenter study. Surgery. 2005;137(4):403–10.

    Article  PubMed  Google Scholar 

  54. Ikai I, Yamamoto Y, Yamamoto N, Terajima H, Hatano E, Shimahara Y, et al. Results of hepatic resection for hepatocellular carcinoma invading major portal and/or hepatic veins. Surg Oncol Clin N Am. 2003;12(1):65–75, ix.

    Article  PubMed  Google Scholar 

  55. Anonymous. Easl-eortc clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56(4):908–43.

    Article  Google Scholar 

  56. Yao FY, Hirose R, LaBerge JM, Davern TJ 3rd, Bass NM, Kerlan RK Jr, et al. A prospective study on downstaging of hepatocellular carcinoma prior to liver transplantation. Liver Transpl. 2005;11(12):1505–14.

    Article  PubMed  Google Scholar 

  57. Yamada R, Nakatsuka H, Nakamura K, Sato M, Itami M, Kobayashi N, et al. Hepatic artery embolization in 32 patients with unresectable hepatoma. Osaka City Med J. 1980;26(2):81–96.

    CAS  PubMed  Google Scholar 

  58. Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the precision v study. Cardiovasc Intervent Radiol. 2010;33(1):41–52.

    Article  PubMed  Google Scholar 

  59. Vogl TJ, Lammer J, Lencioni R, Malagari K, Watkinson A, Pilleul F, et al. Liver, gastrointestinal, and cardiac toxicity in intermediate hepatocellular carcinoma treated with precision tace with drug-eluting beads: results from the precision v randomized trial. AJR Am J Roentgenol. 2011;197(4):W562–70.

    Article  PubMed  Google Scholar 

  60. Breedis C, Young G. The blood supply of neoplasms in the liver. Am J Pathol. 1954;30(5):969–77.

    CAS  PubMed  PubMed Central  Google Scholar 

  61. Ridge JA, Bading JR, Gelbard AS, Benua RS, Daly JM. Perfusion of colorectal hepatic metastases. Relative distribution of flow from the hepatic artery and portal vein. Cancer. 1987;59(9):1547–53.

    Article  CAS  PubMed  Google Scholar 

  62. Lencioni R, Crocetti L, De Simone P, Filipponi F. Loco-regional interventional treatment of hepatocellular carcinoma: techniques, outcomes, and future prospects. Transpl Int. 2010;23(7):698–703.

    Article  PubMed  Google Scholar 

  63. Livraghi T, Bolondi L, Lazzaroni S, Marin G, Morabito A, Rapaccini GL, et al. Percutaneous ethanol injection in the treatment of hepatocellular carcinoma in cirrhosis. A study on 207 patients. Cancer. 1992;69(4):925–9.

    Article  CAS  PubMed  Google Scholar 

  64. Sala M, Llovet JM, Vilana R, Bianchi L, Sole M, Ayuso C, et al. Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatology. 2004;40(6):1352–60.

    Article  PubMed  Google Scholar 

  65. Kuang M, Lu MD, Xie XY, Xu HX, Xu ZF, Liu GJ, et al. Ethanol ablation of hepatocellular carcinoma up to 5.0 cm by using a multipronged injection needle with high-dose strategy. Radiology. 2009;253(2):552–61.

    Article  PubMed  Google Scholar 

  66. Shiina S, Teratani T, Obi S, Sato S, Tateishi R, Fujishima T, et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology. 2005;129(1):122–30.

    Article  PubMed  Google Scholar 

  67. Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC. Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut. 2005;54(8):1151–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Brunello F, Veltri A, Carucci P, Pagano E, Ciccone G, Moretto P, et al. Radiofrequency ablation versus ethanol injection for early hepatocellular carcinoma: a randomized controlled trial. Scand J Gastroenterol. 2008;43(6):727–35.

    Article  PubMed  Google Scholar 

  69. Lencioni RA, Allgaier HP, Cioni D, Olschewski M, Deibert P, Crocetti L, et al. Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology. 2003;228(1):235–40.

    Article  PubMed  Google Scholar 

  70. Livraghi T, Meloni F, Di Stasi M, Rolle E, Solbiati L, Tinelli C, et al. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: is resection still the treatment of choice? Hepatology. 2008;47(1):82–9.

    Article  PubMed  Google Scholar 

  71. Ahrar K, Matin S, Wood CG, Wallace MJ, Gupta S, Madoff DC, et al. Percutaneous radiofrequency ablation of renal tumors: technique, complications, and outcomes. J Vasc Interv Radiol. 2005;16(5):679–88.

    Article  PubMed  Google Scholar 

  72. Simon CJ, Dupuy DE, Mayo-Smith WW. Microwave ablation: principles and applications. Radiographics. 2005;25(Suppl 1):S69–83.

    Article  PubMed  Google Scholar 

  73. Lubner MG, Brace CL, Hinshaw JL, Lee FT Jr. Microwave tumor ablation: mechanism of action, clinical results, and devices. J Vasc Interv Radiol. 2010;21(8 Suppl):S192–203.

    Article  PubMed  PubMed Central  Google Scholar 

  74. Yu NC, Raman SS, Kim YJ, Lassman C, Chang X, Lu DS. Microwave liver ablation: influence of hepatic vein size on heat-sink effect in a porcine model. J Vasc Interv Radiol. 2008;19(7):1087–92.

    Article  PubMed  Google Scholar 

  75. Gage AA, Baust J. Mechanisms of tissue injury in cryosurgery. Cryobiology. 1998;37(3):171–86.

    Article  CAS  PubMed  Google Scholar 

  76. Bageacu S, Kaczmarek D, Lacroix M, Dubois J, Forest J, Porcheron J. Cryosurgery for resectable and unresectable hepatic metastases from colorectal cancer. Eur J Surg Oncol. 2007;33(5):590–6.

    Article  CAS  PubMed  Google Scholar 

  77. Seifert JK, France MP, Zhao J, Bolton EJ, Finlay I, Junginger T, et al. Large volume hepatic freezing: association with significant release of the cytokines interleukin-6 and tumor necrosis factor a in a rat model. World J Surg. 2002;26(11):1333–41.

    Article  PubMed  Google Scholar 

  78. Sheen AJ, Poston GJ, Sherlock DJ. Cryotherapeutic ablation of liver tumours. Br J Surg. 2002;89(11):1396–401.

    Article  CAS  PubMed  Google Scholar 

  79. Wang W, Shi J, Xie WF. Transarterial chemoembolization in combination with percutaneous ablation therapy in unresectable hepatocellular carcinoma: a meta-analysis. Liver Int. 2010;30(5):741–9.

    Article  PubMed  Google Scholar 

  80. Veltri A, Moretto P, Doriguzzi A, Pagano E, Carrara G, Gandini G. Radiofrequency thermal ablation (rfa) after transarterial chemoembolization (tace) as a combined therapy for unresectable non-early hepatocellular carcinoma (hcc). Eur Radiol. 2006;16(3):661–9.

    Article  PubMed  Google Scholar 

  81. Rossi S, Garbagnati F, Lencioni R, Allgaier HP, Marchiano A, Fornari F, et al. Percutaneous radio-frequency thermal ablation of nonresectable hepatocellular carcinoma after occlusion of tumor blood supply. Radiology. 2000;217(1):119–26.

    Article  CAS  PubMed  Google Scholar 

  82. Yamasaki T, Kurokawa F, Shirahashi H, Kusano N, Hironaka K, Okita K. Percutaneous radiofrequency ablation therapy for patients with hepatocellular carcinoma during occlusion of hepatic blood flow. Comparison with standard percutaneous radiofrequency ablation therapy. Cancer. 2002;95(11):2353–60.

    Article  PubMed  Google Scholar 

  83. Lencioni R, Crocetti L, Petruzzi P, Vignali C, Bozzi E, Della Pina C, et al. Doxorubicin-eluting bead-enhanced radiofrequency ablation of hepatocellular carcinoma: a pilot clinical study. J Hepatol. 2008;49(2):217–22.

    Article  CAS  PubMed  Google Scholar 

  84. Gervais DA, Goldberg SN, Brown DB, Soulen MC, Millward SF, Rajan DK. Society of interventional radiology position statement on percutaneous radiofrequency ablation for the treatment of liver tumors. J Vasc Interv Radiol. 2009;20(1):3–8.

    Article  PubMed  Google Scholar 

  85. Cho YK, Kim JK, Kim WT, Chung JW. Hepatic resection versus radiofrequency ablation for very early stage hepatocellular carcinoma: a markov model analysis. Hepatology. 2010;51(4):1284–90.

    Article  PubMed  Google Scholar 

  86. Lencioni R, Crocetti L. Local-regional treatment of hepatocellular carcinoma. Radiology. 2012;262(1):43–58.

    Article  PubMed  Google Scholar 

  87. Germani G, Pleguezuelo M, Gurusamy K, Meyer T, Isgro G, Burroughs AK. Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic acid injection for hepatocelullar carcinoma: a meta-analysis. J Hepatol. 2010;52(3):380–8.

    Article  CAS  PubMed  Google Scholar 

  88. Bouza C, Lopez-Cuadrado T, Alcazar R, Saz-Parkinson Z, Amate JM. Meta-analysis of percutaneous radiofrequency ablation versus ethanol injection in hepatocellular carcinoma. BMC Gastroenterol. 2009;9:31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  89. Shibata T, Iimuro Y, Yamamoto Y, Maetani Y, Ametani F, Itoh K, et al. Small hepatocellular carcinoma: comparison of radio-frequency ablation and percutaneous microwave coagulation therapy. Radiology. 2002;223(2):331–7.

    Article  PubMed  Google Scholar 

  90. Morimoto M, Numata K, Kondo M, Moriya S, Morita S, Maeda S, et al. Radiofrequency ablation combined with transarterial chemoembolization for subcapsular hepatocellular carcinoma: a prospective cohort study. Eur J Radiol. 2013;82(3):497–503.

    Article  PubMed  Google Scholar 

  91. Morimoto M, Numata K, Kondou M, Nozaki A, Morita S, Tanaka K. Midterm outcomes in patients with intermediate-sized hepatocellular carcinoma: a randomized controlled trial for determining the efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization. Cancer. 2010;116(23):5452–60.

    Article  PubMed  Google Scholar 

  92. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology. 2003;37(2):429–42.

    Article  CAS  PubMed  Google Scholar 

  93. Cabibbo G, Enea M, Attanasio M, Bruix J, Craxi A, Camma C. A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. Hepatology. 2010;51(4):1274–83.

    Article  PubMed  Google Scholar 

  94. Burrel M, Reig M, Forner A, Barrufet M, de Lope CR, Tremosini S, et al. Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (tace) using drug eluting beads. Implications for clinical practice and trial design. J Hepatol. 2012;56(6):1330–5.

    Article  PubMed  Google Scholar 

  95. Mazzaferro V, Sposito C, Bhoori S, Romito R, Chiesa C, Morosi C, et al. Yttrium(90) radioembolization for intermediate-advanced hepatocarcinoma: a phase ii study. Hepatology. 2013;57(5):1826–37.

    Article  CAS  PubMed  Google Scholar 

  96. Sangro B, Carpanese L, Cianni R, Golfieri R, Gasparini D, Ezziddin S, et al. Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across barcelona clinic liver cancer stages: a european evaluation. Hepatology. 2011;54(3):868–78.

    Article  PubMed  Google Scholar 

  97. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–90.

    Article  CAS  PubMed  Google Scholar 

  98. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the asia-pacific region with advanced hepatocellular carcinoma: a phase iii randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25–34.

    Article  CAS  PubMed  Google Scholar 

  99. Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, et al. Phase ii study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006;24(26):4293–300.

    Article  CAS  PubMed  Google Scholar 

  100. Park JW, Koh YH, Kim HB, Kim HY, An S, Choi JI, et al. Phase ii study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma. J Hepatol. 2012;56(6):1336–42.

    Article  CAS  PubMed  Google Scholar 

  101. Pawlik TM, Reyes DK, Cosgrove D, Kamel IR, Bhagat N, Geschwind JF. Phase ii trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. J Clin Oncol. 2011;29(30):3960–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  102. Austin-Seymour MM, Chen GT, Castro JR, Saunders WM, Pitluck S, Woodruff KH, et al. Dose volume histogram analysis of liver radiation tolerance. Int J Radiat Oncol Biol Phys. 1986;12(1):31–5.

    Article  CAS  PubMed  Google Scholar 

  103. Lawrence TS, Ten Haken RK, Kessler ML, Robertson JM, Lyman JT, Lavigne ML, et al. The use of 3-d dose volume analysis to predict radiation hepatitis. Int J Radiat Oncol Biol Phys. 1992;23(4):781–8.

    Article  CAS  PubMed  Google Scholar 

  104. Dawson LA, Ten Haken RK. Partial volume tolerance of the liver to radiation. Semin Radiat Oncol. 2005;15(4):279–83.

    Article  PubMed  Google Scholar 

  105. Dawson LA, McGinn CJ, Normolle D, Ten Haken RK, Walker S, Ensminger W, et al. Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies. J Clin Oncol. 2000;18(11):2210–8.

    Article  CAS  PubMed  Google Scholar 

  106. Wurm RE, Gum F, Erbel S, Schlenger L, Scheffler D, Agaoglu D, et al. Image guided respiratory gated hypofractionated stereotactic body radiation therapy (h-sbrt) for liver and lung tumors: initial experience. Acta Oncol. 2006;45(7):881–9.

    Article  CAS  PubMed  Google Scholar 

  107. Brock KK, Dawson LA. Adaptive management of liver cancer radiotherapy. Semin Radiat Oncol. 2010;20(2):107–15.

    Article  PubMed  PubMed Central  Google Scholar 

  108. Verellen D, Depuydt T, Gevaert T, Linthout N, Tournel K, Duchateau M, et al. Gating and tracking, 4d in thoracic tumours. Cancer Radiotherapie: journal de la Societe francaise de radiotherapie oncologique. 2010;14(6–7):446–54.

    Article  CAS  Google Scholar 

  109. Iizuka Y, Matsuo Y, Ishihara Y, Akimoto M, Tanabe H, Takayama K, et al. Dynamic tumor-tracking radiotherapy with real-time monitoring for liver tumors using a gimbal mounted linac. Radiother Oncol. 2015;117(3):496–500.

    Article  PubMed  Google Scholar 

  110. Eccles C, Brock KK, Bissonnette JP, Hawkins M, Dawson LA. Reproducibility of liver position using active breathing coordinator for liver cancer radiotherapy. Int J Radiat Oncol Biol Phys. 2006;64(3):751–9.

    Article  PubMed  Google Scholar 

  111. Dawson LA, Brock KK, Kazanjian S, Fitch D, McGinn CJ, Lawrence TS, et al. The reproducibility of organ position using active breathing control (abc) during liver radiotherapy. Int J Radiat Oncol Biol Phys. 2001;51(5):1410–21.

    Article  CAS  PubMed  Google Scholar 

  112. Tina Marie B, Sam B, Peter B, Ravi M, Sanjay G, Christopher N, et al. Respiratory gating with epid-based verification: the mdacc experience. Phys Med Biol. 2009;54(11):3379.

    Article  Google Scholar 

  113. Heinzerling JH, Anderson JF, Papiez L, Boike T, Chien S, Zhang G, et al. Four-dimensional computed tomography scan analysis of tumor and organ motion at varying levels of abdominal compression during stereotactic treatment of lung and liver. Int J Radiat Oncol Biol Phys. 2008;70(5):1571–8.

    Article  PubMed  Google Scholar 

  114. Lovelock DM, Zatcky J, Goodman K, Yamada Y. The effectiveness of a pneumatic compression belt in reducing respiratory motion of abdominal tumors in patients undergoing stereotactic body radiotherapy. Technol Cancer Res Treat. 2014;13(3):259–67.

    Article  PubMed  Google Scholar 

  115. Timmerman R, McGarry R, Yiannoutsos C, Papiez L, Tudor K, DeLuca J, et al. Excessive toxicity when treating central tumors in a phase ii study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol. 2006;24(30):4833–9.

    Article  PubMed  Google Scholar 

  116. Dawson LA, Eccles C, Craig T. Individualized image guided iso-ntcp based liver cancer sbrt. Acta Oncol. 2006;45(7):856–64.

    Article  PubMed  Google Scholar 

  117. Tse RV, Hawkins M, Lockwood G, Kim JJ, Cummings B, Knox J, et al. Phase i study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol. 2008;26(4):657–64.

    Article  PubMed  Google Scholar 

  118. Bujold A, Massey CA, Kim JJ, Brierley J, Cho C, Wong RKS, et al. Sequential phase i and ii trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. J Clin Oncol. 2013;31(13):1631–9.

    Article  PubMed  Google Scholar 

  119. Wang X, Krishnan S, Zhang X, Dong L, Briere T, Crane CH, et al. Proton radiotherapy for liver tumors: dosimetric advantages over photon plans. Med Dosim. 2008;33(4):259–67.

    Article  PubMed  Google Scholar 

  120. Petersen JB, Lassen Y, Hansen AT, Muren LP, Grau C, Hoyer M. Normal liver tissue sparing by intensity-modulated proton stereotactic body radiotherapy for solitary liver tumours. Acta Oncol. 2011;50(6):823–8.

    Article  PubMed  Google Scholar 

  121. Fukumitsu N, Sugahara S, Nakayama H, Fukuda K, Mizumoto M, Abei M, et al. A prospective study of hypofractionated proton beam therapy for patients with hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2009;74(3):831–6.

    Article  PubMed  Google Scholar 

  122. Kawashima M, Furuse J, Nishio T, Konishi M, Ishii H, Kinoshita T, et al. Phase ii study of radiotherapy employing proton beam for hepatocellular carcinoma. J Clin Oncol. 2005;23(9):1839–46.

    Article  PubMed  Google Scholar 

  123. Mizumoto M, Okumura T, Hashimoto T, Fukuda K, Oshiro Y, Fukumitsu N, et al. Proton beam therapy for hepatocellular carcinoma: a comparison of three treatment protocols. Int J Radiat Oncol Biol Phys. 2011;81(4):1039–45.

    Article  PubMed  Google Scholar 

  124. Tao R, Krishnan S, Bhosale PR, Javle MM, Aloia TA, Shroff RT, Kaseb AO, Bishop AJ, Swanick CW, Koay EJ, Thames HD. Ablative radiotherapy doses lead to a substantial prolongation of survival in patients with inoperable intrahepatic cholangiocarcinoma. J Clin Oncol. 2016;34(3):219.

    Article  CAS  PubMed  Google Scholar 

  125. Crane C, Koay EJ. Solutions that enable ablative radiotherapy for large liver tumors: fractionated dose painting, simultaneous integrated protection, motion management, and computed tomography image guidance. Cancer. 2016;122(13):1974–86.

    Article  PubMed  Google Scholar 

  126. Seong J, Koom WS, Park HC. Radiotherapy for painful bone metastases from hepatocellular carcinoma. Liver Int. 2005;25(2):261–5.

    Article  PubMed  Google Scholar 

  127. Kaizu T, Karasawa K, Tanaka Y, Matuda T, Kurosaki H, Tanaka S, et al. Radiotherapy for osseous metastases from hepatocellular carcinoma: a retrospective study of 57 patients. Am J Gastroenterol. 1998;93(11):2167–71.

    Article  CAS  PubMed  Google Scholar 

  128. Hawkins MA, Dawson LA. Radiation therapy for hepatocellular carcinoma: from palliation to cure. Cancer. 2006;106(8):1653–63.

    Article  PubMed  Google Scholar 

  129. Jiang W, Zeng ZC, Zhang JY, Fan J, Zeng MS, Zhou J. Palliative radiation therapy for pulmonary metastases from hepatocellular carcinoma. Clin Exp Metastasis. 2012;29(3):197–205.

    Article  CAS  PubMed  Google Scholar 

  130. Toya R, Murakami R, Baba Y, Nishimura R, Morishita S, Ikeda O, et al. Conformal radiation therapy for portal vein tumor thrombosis of hepatocellular carcinoma. Radiother Oncol. 2007;84(3):266–71.

    Article  PubMed  Google Scholar 

  131. Tazawa J, Maeda M, Sakai Y, Yamane M, Ohbayashi H, Kakinuma S, et al. Radiation therapy in combination with transcatheter arterial chemoembolization for hepatocellular carcinoma with extensive portal vein involvement. J Gastroenterol Hepatol. 2001;16(6):660–5.

    Article  CAS  PubMed  Google Scholar 

  132. Gayou O, Day E, Mohammadi S, Kirichenko A. A method for registration of single photon emission computed tomography (spect) and computed tomography (ct) images for liver stereotactic radiotherapy (srt). Med Phys. 2012;39(12):7398–401.

    Article  PubMed  Google Scholar 

  133. Hoefs JC, Wang F, Kanel G. Functional measurement of nonfibrotic hepatic mass in cirrhotic patients. Am J Gastroenterol. 1997;92(11):2054–8.

    CAS  PubMed  Google Scholar 

  134. Wisse E, Braet F, Luo D, De Zanger R, Jans D, Crabbe E, et al. Structure and function of sinusoidal lining cells in the liver. Toxicol Pathol. 1996;24(1):100–11.

    Article  CAS  PubMed  Google Scholar 

  135. Kirichenko A, Gayou O, Day E, Lappinen E, Thai N, Parda D. Stereotactic radiotherapy (srt) for hepatocellular carcinoma (hcc) with 3-d ct and single photon emission computed tomography (ct/spect) functional treatment planning. Int J Radiat Oncol Biol Phys. 2014; In review.

    Google Scholar 

  136. Nowak AK, Chow PK, Findlay M. Systemic therapy for advanced hepatocellular carcinoma: a review. Eur J Cancer. 2004;40(10):1474–84.

    Article  CAS  PubMed  Google Scholar 

  137. Palmer DH, Hussain SA, Johnson PJ. Systemic therapies for hepatocellular carcinoma. Expert Opin Investig Drugs. 2004;13(12):1555–68.

    Article  CAS  PubMed  Google Scholar 

  138. Thomas MB, Morris JS, Chadha R, Iwasaki M, Kaur H, Lin E, et al. Phase ii trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol. 2009;27(6):843–50.

    Article  CAS  PubMed  Google Scholar 

  139. Olweny CL, Toya T, Katongole-Mbidde E, Mugerwa J, Kyalwazi SK, Cohen H. Treatment of hepatocellular carcinoma with adriamycin. Preliminary communication. Cancer. 1975;36(4):1250–7.

    Article  CAS  PubMed  Google Scholar 

  140. Falkson G, Moertel CG, Lavin P, Pretorius FJ, Carbone PP. Chemotherapy studies in primary liver cancer: a prospective randomized clinical trial. Cancer. 1978;42(5):2149–56.

    Article  CAS  PubMed  Google Scholar 

  141. Tetef M, Doroshow J, Akman S, Coluzzi P, Leong L, Margolin K, et al. 5-fluorouracil and high-dose calcium leucovorin for hepatocellular carcinoma: a phase ii trial. Cancer Investig. 1995;13(5):460–3.

    Article  CAS  Google Scholar 

  142. Link JS, Bateman JR, Paroly WS, Durkin WJ, Peters RL. 5-flourouracil in hepatocellular carcinoma: report of twenty-one cases. Cancer. 1977;39(5):1936–9.

    Article  CAS  PubMed  Google Scholar 

  143. Porta C, Moroni M, Nastasi G, Arcangeli G. 5-fluorouracil and d,l-leucovorin calcium are active to treat unresectable hepatocellular carcinoma patients: preliminary results of a phase ii study. Oncology. 1995;52(6):487–91.

    Article  CAS  PubMed  Google Scholar 

  144. Chambers CA, Sullivan TJ, Allison JP. Lymphoproliferation in ctla-4-deficient mice is mediated by costimulation-dependent activation of cd4+ t cells. Immunity. 1997;7(6):885–95.

    Article  CAS  PubMed  Google Scholar 

  145. Friedman MA. Primary hepatocellular cancer--present results and future prospects. Int J Radiat Oncol Biol Phys. 1983;9(12):1841–50.

    Article  CAS  PubMed  Google Scholar 

  146. Walko CM, Lindley C. Capecitabine: a review. Clin Ther. 2005;27(1):23–44.

    Article  CAS  PubMed  Google Scholar 

  147. Xia Y, Qiu Y, Li J, Shi L, Wang K, Xi T, et al. Adjuvant therapy with capecitabine postpones recurrence of hepatocellular carcinoma after curative resection: a randomized controlled trial. Ann Surg Oncol. 2010;17(12):3137–44.

    Article  PubMed  Google Scholar 

  148. Fuchs CS, Clark JW, Ryan DP, Kulke MH, Kim H, Earle CC, et al. A phase ii trial of gemcitabine in patients with advanced hepatocellular carcinoma. Cancer. 2002;94(12):3186–91.

    Article  CAS  PubMed  Google Scholar 

  149. Kubicka S, Rudolph KL, Tietze MK, Lorenz M, Manns M. Phase ii study of systemic gemcitabine chemotherapy for advanced unresectable hepatobiliary carcinomas. Hepato-Gastroenterology. 2001;48(39):783–9.

    CAS  PubMed  Google Scholar 

  150. Yang TS, Lin YC, Chen JS, Wang HM, Wang CH. Phase ii study of gemcitabine in patients with advanced hepatocellular carcinoma. Cancer. 2000;89(4):750–6.

    Article  CAS  PubMed  Google Scholar 

  151. Boige V, Taieb J, Hebbar M, Malka D, Debaere T, Hannoun L, et al. Irinotecan as first-line chemotherapy in patients with advanced hepatocellular carcinoma: a multicenter phase ii study with dose adjustment according to baseline serum bilirubin level. Eur J Cancer. 2006;42(4):456–9.

    Article  CAS  PubMed  Google Scholar 

  152. Hsu C, Chen CN, Chen LT, Wu CY, Yang PM, Lai MY, et al. Low-dose thalidomide treatment for advanced hepatocellular carcinoma. Oncology. 2003;65(3):242–9.

    Article  CAS  PubMed  Google Scholar 

  153. Chao Y, Chan WK, Birkhofer MJ, Hu OY, Wang SS, Huang YS, et al. Phase ii and pharmacokinetic study of paclitaxel therapy for unresectable hepatocellular carcinoma patients. Br J Cancer. 1998;78(1):34–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  154. Lin HL, Liu TY, Chau GY, Lui WY, Chi CW. Comparison of 2-methoxyestradiol-induced, docetaxel-induced, and paclitaxel-induced apoptosis in hepatoma cells and its correlation with reactive oxygen species. Cancer. 2000;89(5):983–94.

    Article  CAS  PubMed  Google Scholar 

  155. Okada S, Okazaki N, Nose H, Shimada Y, Yoshimori M, Aoki K. A phase 2 study of cisplatin in patients with hepatocellular carcinoma. Oncology. 1993;50(1):22–6.

    Article  CAS  PubMed  Google Scholar 

  156. Morstyn G, Ihde DC, Eddy JL, Bunn PA, Cohen MH, Minna JD. Combination chemotherapy of hepatocellular carcinoma with doxorubicin and streptozotocin. Am J Clin Oncol. 1983;6(5):547–51.

    Article  CAS  PubMed  Google Scholar 

  157. Chlebowski RT, Chan KK, Tong MJ, Weiner JM, Ryden VM, Bateman JR. Adriamycin and methyl-ccnu combination therapy in hepatocellular carcinoma: clinical and pharmacokinetic aspects. Cancer. 1981;48(5):1088–95.

    Article  CAS  PubMed  Google Scholar 

  158. Falkson CI, Falkson G. A phase ii evaluation of clofazimine plus doxorubicin in advanced, unresectable primary hepatocellular carcinoma. Oncology. 1999;57(3):232–5.

    Article  CAS  PubMed  Google Scholar 

  159. Yang TS, Wang CH, Hsieh RK, Chen JS, Fung MC. Gemcitabine and doxorubicin for the treatment of patients with advanced hepatocellular carcinoma: a phase i-ii trial. Ann Oncol. 2002;13(11):1771–8.

    Article  CAS  PubMed  Google Scholar 

  160. Ellis PA, Norman A, Hill A, O’Brien ME, Nicolson M, Hickish T, et al. Epirubicin, cisplatin and infusional 5-fluorouracil (5-fu) (ecf) in hepatobiliary tumours. Eur J Cancer. 1995;31A(10):1594–8.

    Article  CAS  PubMed  Google Scholar 

  161. Boucher E, Corbinais S, Brissot P, Boudjema K, Raoul JL. Treatment of hepatocellular carcinoma (hcc) with systemic chemotherapy combining epirubicin, cisplatinum and infusional 5-fluorouracil (ecf regimen). Cancer Chemother Pharmacol. 2002;50(4):305–8.

    Article  CAS  PubMed  Google Scholar 

  162. Leung TW, Tang AM, Zee B, Yu SC, Lai PB, Lau WY, et al. Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy. Cancer. 2002;94(2):421–7.

    Article  CAS  PubMed  Google Scholar 

  163. Kajanti MJ, Pyrhonen SO. Phase ii intravenous study of epirubicin with 5-fluorouracil in patients with advanced hepatocellular carcinoma. Eur J Cancer. 1991;27(12):1620–2.

    Article  CAS  PubMed  Google Scholar 

  164. Al-Idrissi HY, Ibrahim EM, Abdel Satir A, Satti MB, Al-Kasem S, Al-Qurain A. Primary hepatocellular carcinoma in the eastern province of saudi arabia: treatment with combination chemotherapy using 5-fluorouracil, adriamycin and mitomycin-c. Hepato-Gastroenterology. 1985;32(1):8–10.

    CAS  PubMed  Google Scholar 

  165. Shim JH, Park JW, Nam BH, Lee WJ, Kim CM. Efficacy of combination chemotherapy with capecitabine plus cisplatin in patients with unresectable hepatocellular carcinoma. Cancer Chemother Pharmacol. 2009;63(3):459–67.

    Article  CAS  PubMed  Google Scholar 

  166. Lee JO, Lee KW, Oh DY, Kim JH, Im SA, Kim TY, et al. Combination chemotherapy with capecitabine and cisplatin for patients with metastatic hepatocellular carcinoma. Ann Oncol. 2009;20(8):1402–7.

    Article  CAS  PubMed  Google Scholar 

  167. Lombardi G, Zustovich F, Farinati F, Cillo U, Vitale A, Zanus G, et al. Pegylated liposomal doxorubicin and gemcitabine in patients with advanced hepatocellular carcinoma: results of a phase 2 study. Cancer. 2011;117(1):125–33.

    Article  CAS  PubMed  Google Scholar 

  168. Louafi S, Boige V, Ducreux M, Bonyhay L, Mansourbakht T, de Baere T, et al. Gemcitabine plus oxaliplatin (gemox) in patients with advanced hepatocellular carcinoma (hcc): results of a phase ii study. Cancer. 2007;109(7):1384–90.

    Article  CAS  PubMed  Google Scholar 

  169. Qin S, Cheng Y, Liang J, Shen L, Bai Y, Li J, et al. Efficacy and safety of the folfox4 regimen versus doxorubicin in chinese patients with advanced hepatocellular carcinoma: a subgroup analysis of the each study. Oncologist. 2014;19(11):1169–78.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  170. Yeo W, Mok TS, Zee B, Leung TW, Lai PB, Lau WY, et al. A randomized phase iii study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (piaf) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst. 2005;97(20):1532–8.

    Article  CAS  PubMed  Google Scholar 

  171. Kaseb AO, Shindoh J, Patt YZ, Roses RE, Zimmitti G, Lozano RD, et al. Modified cisplatin/interferon alpha-2b/doxorubicin/5-fluorouracil (piaf) chemotherapy in patients with no hepatitis or cirrhosis is associated with improved response rate, resectability, and survival of initially unresectable hepatocellular carcinoma. Cancer. 2013;119(18):3334–42.

    Article  CAS  PubMed  Google Scholar 

  172. Huang CC, Wu MC, Xu GW, Li DZ, Cheng H, Tu ZX, et al. Overexpression of the mdr1 gene and p-glycoprotein in human hepatocellular carcinoma. J Natl Cancer Inst. 1992;84(4):262–4.

    Article  CAS  PubMed  Google Scholar 

  173. Semela D, Dufour JF. Angiogenesis and hepatocellular carcinoma. J Hepatol. 2004;41(5):864–80.

    Article  PubMed  Google Scholar 

  174. O’Neil BH, Goff LW, Kauh JS, Strosberg JR, Bekaii-Saab TS, Lee RM, et al. Phase ii study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2011;29(17):2350–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  175. Lee J, Park JO, Kim WS, Park SH, Park KW, Choi MS, et al. Phase ii study of doxorubicin and cisplatin in patients with metastatic hepatocellular carcinoma. Cancer Chemother Pharmacol. 2004;54(5):385–90.

    Article  CAS  PubMed  Google Scholar 

  176. Parikh PM, Fuloria J, Babu G, Doval DC, Awasthy BS, Pai VR, et al. A phase ii study of gemcitabine and cisplatin in patients with advanced hepatocellular carcinoma. Trop Gastroenterol. 2005;26(3):115–8.

    CAS  PubMed  Google Scholar 

  177. Zaanan A, Williet N, Hebbar M, Dabakuyo TS, Fartoux L, Mansourbakht T, et al. Gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma: a large multicenter ageo study. J Hepatol. 2013;58(1):81–8.

    Article  CAS  PubMed  Google Scholar 

  178. Leung TW, Patt YZ, Lau WY, Ho SK, Yu SC, Chan AT, et al. Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. Clin Cancer Res. 1999;5(7):1676–81.

    CAS  PubMed  Google Scholar 

  179. Abou-Alfa GK, Johnson P, Knox JJ, Capanu M, Davidenko I, Lacava J, et al. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA. 2010;304(19):2154–60.

    Article  CAS  PubMed  Google Scholar 

  180. Siegel AB, Cohen EI, Ocean A, Lehrer D, Goldenberg A, Knox JJ, et al. Phase ii trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol. 2008;26(18):2992–8.

    Article  CAS  PubMed  Google Scholar 

  181. Cheng AL, Kang YK, Lin DY, Park JW, Kudo M, Qin S, et al. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase iii trial. J Clin Oncol. 2013;31(32):4067–75.

    Article  CAS  PubMed  Google Scholar 

  182. McNamara MG, Le LW, Horgan AM, Aspinall A, Burak KW, Dhani N, et al. A phase ii trial of second-line axitinib following prior antiangiogenic therapy in advanced hepatocellular carcinoma. Cancer. 2015;121(10):1620–7.

    Article  CAS  PubMed  Google Scholar 

  183. Zhu AX, Rosmorduc O, Evans TR, Ross PJ, Santoro A, Carrilho FJ, et al. Search: a phase iii, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2015;33(6):559–66.

    Article  CAS  PubMed  Google Scholar 

  184. Kaseb AO, Garrett-Mayer E, Morris JS, Xiao L, Lin E, Onicescu G, et al. Efficacy of bevacizumab plus erlotinib for advanced hepatocellular carcinoma and predictors of outcome: final results of a phase ii trial. Oncology. 2012;82(2):67–74.

    Article  CAS  PubMed  Google Scholar 

  185. Kaseb AO, Morris JS, Iwasaki M, Al-Shamsi HO, Raghav KP, Girard L, et al. Phase ii trial of bevacizumab and erlotinib as a second-line therapy for advanced hepatocellular carcinoma. Onco Targets Ther. 2016;9:773–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  186. Johnson PJ, Qin S, Park JW, Poon RT, Raoul JL, Philip PA, et al. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase iii brisk-fl study. J Clin Oncol. 2013;31(28):3517–24.

    Article  CAS  PubMed  Google Scholar 

  187. Llovet JM, Decaens T, Raoul JL, Boucher E, Kudo M, Chang C, et al. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase iii brisk-ps study. J Clin Oncol. 2013;31(28):3509–16.

    Article  CAS  PubMed  Google Scholar 

  188. Zhu AX, Kudo M, Assenat E, Cattan S, Kang YK, Lim HY, et al. Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the evolve-1 randomized clinical trial. JAMA. 2014;312(1):57–67.

    Article  CAS  PubMed  Google Scholar 

  189. Santoro A, Rimassa L, Borbath I, Daniele B, Salvagni S, Van Laethem JL, et al. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. Lancet Oncol. 2013;14(1):55–63.

    Article  CAS  PubMed  Google Scholar 

  190. El-Khoueiry A, Melero I, Crocenzi T, Welling T, Yau TC, Yeo W, et al. Phase i/ii safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (hcc): Ca209-040. J Clin Oncol. 2015;33(suppl; abstr):LBA101.

    Article  Google Scholar 

  191. Bruix J, Raoul JL, Sherman M, Mazzaferro V, Bolondi L, Craxi A, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase iii trial. J Hepatol. 2012;57(4):821–9.

    Article  CAS  PubMed  Google Scholar 

  192. Wilhelm SM, Dumas J, Adnane L, Lynch M, Carter CA, Schutz G, et al. Regorafenib (bay 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer. 2011;129(1):245–55.

    Article  CAS  PubMed  Google Scholar 

  193. Zhu AX, Park JO, Ryoo BY, Yen CJ, Poon R, Pastorelli D, et al. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (reach): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2015;16(7):859–70.

    Article  CAS  PubMed  Google Scholar 

  194. Abou-Alfa G, Qin S, Ryoo B, editors. Phase iii randomized study of second line adi-peg 20 (a) plus best supportive care versus placebo (p) plus best supportive care in patients (pts) with advanced hepatocellular carcinoma (hcc). Proc Am Soc Clin Oncol; 2016.

    Google Scholar 

  195. Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (resorce): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389(10064):56–66.

    Article  CAS  PubMed  Google Scholar 

  196. Telli ML, Witteles RM, Fisher GA, Srinivas S. Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. Ann Oncol. 2008;19(9):1613–8.

    Article  CAS  PubMed  Google Scholar 

  197. Faivre S, Raymond E, Boucher E, Douillard J, Lim HY, Kim JS, et al. Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase ii study. Lancet Oncol. 2009;10(8):794–800.

    Article  CAS  PubMed  Google Scholar 

  198. Zhu AX, Sahani DV, Duda DG, di Tomaso E, Ancukiewicz M, Catalano OA, et al. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase ii study. J Clin Oncol. 2009;27(18):3027–35.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  199. Boige V, Malka D, Bourredjem A, Dromain C, Baey C, Jacques N, et al. Efficacy, safety, and biomarkers of single-agent bevacizumab therapy in patients with advanced hepatocellular carcinoma. Oncologist. 2012;17(8):1063–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  200. Govindarajan R, Siegel E, Makhoul I, Williamson S. Bevacizumab and erlotinib in previously untreated inoperable and metastatic hepatocellular carcinoma. Am J Clin Oncol. 2013;36(3):254–7.

    Article  CAS  PubMed  Google Scholar 

  201. Yau T, Wong H, Chan P, Yao TJ, Pang R, Cheung TT, et al. Phase ii study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma patients with sorafenib-refractory disease. Investig New Drugs. 2012;30(6):2384–90.

    Article  CAS  Google Scholar 

  202. Philip PA, Mahoney MR, Holen KD, Northfelt DW, Pitot HC, Picus J, et al. Phase 2 study of bevacizumab plus erlotinib in patients with advanced hepatocellular cancer. Cancer. 2012;118(9):2424–30.

    Article  CAS  PubMed  Google Scholar 

  203. Zhu AX, Blaszkowsky LS, Ryan DP, Clark JW, Muzikansky A, Horgan K, et al. Phase ii study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006;24(12):1898–903.

    Article  CAS  PubMed  Google Scholar 

  204. Hsu CH, Yang TS, Hsu C, Toh HC, Epstein RJ, Hsiao LT, et al. Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma. Br J Cancer. 2010;102(6):981–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  205. Sun W, Sohal D, Haller DG, Mykulowycz K, Rosen M, Soulen MC, et al. Phase 2 trial of bevacizumab, capecitabine, and oxaliplatin in treatment of advanced hepatocellular carcinoma. Cancer. 2011;117(14):3187–92.

    Article  CAS  PubMed  Google Scholar 

  206. Escudier B, Gore M. Axitinib for the management of metastatic renal cell carcinoma. Drugs R&D. 2011;11(2):113–26.

    Article  Google Scholar 

  207. Hu-Lowe DD, Zou HY, Grazzini ML, Hallin ME, Wickman GR, Amundson K, et al. Nonclinical antiangiogenesis and antitumor activities of axitinib (ag-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res. 2008;14(22):7272–83.

    Article  CAS  PubMed  Google Scholar 

  208. Ayers M, Fargnoli J, Lewin A, Wu Q, Platero JS. Discovery and validation of biomarkers that respond to treatment with brivanib alaninate, a small-molecule vegfr-2/fgfr-1 antagonist. Cancer Res. 2007;67(14):6899–906.

    Article  CAS  PubMed  Google Scholar 

  209. Cai ZW, Zhang Y, Borzilleri RM, Qian L, Barbosa S, Wei D, et al. Discovery of brivanib alaninate ((s)-((r)-1-(4-(4-fluoro-2-methyl-1h-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4] triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (bms-540215). J Med Chem. 2008;51(6):1976–80.

    Article  CAS  PubMed  Google Scholar 

  210. Park JW, Finn RS, Kim JS, Karwal M, Li RK, Ismail F, et al. Phase ii, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma. Clin Cancer Res. 2011;17(7):1973–83.

    Article  CAS  PubMed  Google Scholar 

  211. Hay N, Sonenberg N. Upstream and downstream of mtor. Genes Dev. 2004;18(16):1926–45.

    Article  CAS  PubMed  Google Scholar 

  212. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al. Tumor-associated b7-h1 promotes t-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8(8):793–800.

    Article  CAS  PubMed  Google Scholar 

  213. Konishi J, Yamazaki K, Azuma M, Kinoshita I, Dosaka-Akita H, Nishimura M. B7-h1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their pd-1 expression. Clin Cancer Res. 2004;10(15):5094–100.

    Article  CAS  PubMed  Google Scholar 

  214. Brown JA, Dorfman DM, Ma FR, Sullivan EL, Munoz O, Wood CR, et al. Blockade of programmed death-1 ligands on dendritic cells enhances t cell activation and cytokine production. J Immunol. 2003;170(3):1257–66.

    Article  CAS  PubMed  Google Scholar 

  215. Gao Q, Wang XY, Qiu SJ, Yamato I, Sho M, Nakajima Y, et al. Overexpression of pd-l1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin Cancer Res. 2009;15(3):971–9.

    Article  CAS  PubMed  Google Scholar 

  216. Sangro B, Gomez-Martin C, de la Mata M, Inarrairaegui M, Garralda E, Barrera P, et al. A clinical trial of ctla-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis c. J Hepatol. 2013;59(1):81–8.

    Article  CAS  PubMed  Google Scholar 

  217. Kuang DM, Zhao Q, Peng C, Xu J, Zhang JP, Wu C, et al. Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through pd-l1. J Exp Med. 2009;206(6):1327–37.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  218. Andarini S, Kikuchi T, Nukiwa M, Pradono P, Suzuki T, Ohkouchi S, et al. Adenovirus vector-mediated in vivo gene transfer of ox40 ligand to tumor cells enhances antitumor immunity of tumor-bearing hosts. Cancer Res. 2004;64(9):3281–7.

    Article  CAS  PubMed  Google Scholar 

  219. Ishii N, Takahashi T, Soroosh P, Sugamura K. Ox40-ox40 ligand interaction in t-cell-mediated immunity and immunopathology. Adv Immunol. 2010;105:63–98.

    Article  CAS  PubMed  Google Scholar 

  220. Weinberg AD, Morris NP, Kovacsovics-Bankowski M, Urba WJ, Curti BD. Science gone translational: the ox40 agonist story. Immunol Rev. 2011;244(1):218–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  221. Croft M. Control of immunity by the tnfr-related molecule ox40 (cd134). Annu Rev Immunol. 2010;28:57–78.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  222. Zaini J, Andarini S, Tahara M, Saijo Y, Ishii N, Kawakami K, et al. Ox40 ligand expressed by dcs costimulates nkt and cd4+ th cell antitumor immunity in mice. J Clin Invest. 2007;117(11):3330–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  223. Kjaergaard J, Tanaka J, Kim JA, Rothchild K, Weinberg A, Shu S. Therapeutic efficacy of ox-40 receptor antibody depends on tumor immunogenicity and anatomic site of tumor growth. Cancer Res. 2000;60(19):5514–21.

    CAS  PubMed  Google Scholar 

  224. Piconese S, Valzasina B, Colombo MP. Ox40 triggering blocks suppression by regulatory t cells and facilitates tumor rejection. J Exp Med. 2008;205(4):825–39.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  225. Sangro B, Melero I, Yau T, Hsu C, Kudo M, Crocenzi T, et al. Safety and antitumor activity of nivolumab (nivo) in patients (pts) with advanced hepatocellular carcinoma (hcc): interim analysis of dose-expansion cohorts from the phase 1/2 checkmate-040 study. Liver Cancer. 2016.

    Google Scholar 

  226. Scagliotti GV, Novello S, von Pawel J. The emerging role of met/hgf inhibitors in oncology. Cancer Treat Rev. 2013;39(7):793–801.

    Article  CAS  PubMed  Google Scholar 

  227. Xiang QF, Zhang DM, Wang JN, Zhang HW, Zheng ZY, Yu DC, et al. Cabozantinib reverses multidrug resistance of human hepatoma hepg2/adr cells by modulating the function of p-glycoprotein. Liver Int. 2015;35(3):1010–23.

    Article  CAS  PubMed  Google Scholar 

  228. Prior IA, Lewis PD, Mattos C. A comprehensive survey of ras mutations in cancer. Cancer Res. 2012;72(10):2457–67.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  229. Schmidt CM, McKillop IH, Cahill PA, Sitzmann JV. Increased mapk expression and activity in primary human hepatocellular carcinoma. Biochem Biophys Res Commun. 1997;236(1):54–8.

    Article  CAS  PubMed  Google Scholar 

  230. Ito Y, Sasaki Y, Horimoto M, Wada S, Tanaka Y, Kasahara A, et al. Activation of mitogen-activated protein kinases/extracellular signal-regulated kinases in human hepatocellular carcinoma. Hepatology. 1998;27(4):951–8.

    Article  CAS  PubMed  Google Scholar 

  231. Hong YS, Nam BH, Kim KP, Kim JE, Park SJ, Park YS, et al. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (adore): an open-label, multicentre, phase 2, randomised controlled trial. Lancet Oncol. [Clinical Trial, Phase II Comparative Study Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov’t]. 2014;15(11):1245–53.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Hacettepe Üniversitesi Sıhhiye Yerleşkesi, Altındağ, Ankara, Turkey

    Sahin Lacin

  2. Department of Pathology, Division of Pathology/Lab Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Asif Rashid

  3. Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Yun Shin Chun

  4. Department of Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Bruno Calazans Odisio

  5. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Eugene J. Koay

  6. Department of GI Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Reham Abdel-Wahab

  7. Department of GI Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Ahmed O. Kaseb

Authors
  1. Sahin Lacin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Asif Rashid
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yun Shin Chun
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Bruno Calazans Odisio
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Eugene J. Koay
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Reham Abdel-Wahab
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ahmed O. Kaseb
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yun Shin Chun .

Editor information

Editors and Affiliations

  1. Department of Medical Oncology, Hacettepe University Institute of Cancer, Sihhiye, Ankara, Turkey

    Suayib Yalcin

  2. Department of Oncology, Barbara Ann Karmanos Cancer Institute, Detroit, MI, USA

    Philip A. Philip

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Lacin, S. et al. (2019). Hepatocellular Carcinoma. In: Yalcin, S., Philip, P. (eds) Textbook of Gastrointestinal Oncology. Springer, Cham. https://doi.org/10.1007/978-3-030-18890-0_13

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-18890-0_13

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-18888-7

  • Online ISBN: 978-3-030-18890-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation